Recruiting
Phase 2

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

Sponsor:

Davendra Sohal

Code:

NCT05027425

Conditions

Hepatocellular Carcinoma

Cirrhosis

Portal Hypertension

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Durvalumab

Tremelimumab

Liver Transplant

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information